The Food and Drug Administration today authorized Innovative Health Solutions Inc. to market an electrical nerve stimulator device to relieve opioid withdrawal symptoms when placed behind the patient’s ear. Previously approved for use in acupuncture, the NSS-2 Bridge device reduced symptoms for patients undergoing opioid withdrawal during a clinical study by at least 31% within 30 minutes, based on the clinical opiate withdrawal scale. Sixty-four of the 73 patients in the study transitioned to medication assisted therapy after five days using the device. “The FDA is committed to supporting the development of novel treatments, both drugs and devices, that can be used to address opioid dependence or addiction, as well as new, non-addictive treatments for pain that can serve as alternatives to opioids,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
AHA Feb. 15 reiterated its support for the Future Advancement of Academic Nursing Act, recently reintroduced by Sen. Jeff Merkley, D-Ore., and Rep. Lauren…
Headline
Ellen Brzytwa, R.N., a trustee at the Cleveland Clinic, discusses her mission to recruit more nurses to hospital board positions. LISTEN NOW
Headline
Fisher-Titus Medical Center in Norwalk, Ohio, addressed its nursing workforce gap by recruiting international nurses and working to create a welcoming and…
Headline
The Centers for Medicare & Medicaid Services Nov. 15 finalized public reporting requirements for skilled nursing facilities participating in the…
Chairperson's File
On today’s episode, I talk with Mary Beth Kingston, executive vice president and chief nursing officer at Advocate Health. She also is a past president of the…
Headline
The Centers for Medicare & Medicaid Services’ proposal to implement mandatory nurse staffing levels “would have serious, negative, unintended consequences…